‘Advanced Parkinson’s’ is considered to be a controversial term by many. It generally refers to a time when symptoms have become more complex and have a stronger effect on day-to-day life – and when non-oral therapies begin to be considered as a viable option to manage symptoms. In the Hoehn and Yahr rating scale, ‘advanced’ Parkinson’s is represented by stages four and five.
Share what you know about treatments for late-stage Parkinson’s disease
Author: Saskia MairPublished: 1 April 2021
Prep: Cook: Serves:
Research suggests that getting access to non-oral therapies earlier could improve quality of life for some people with Parkinson’s disease – but that most don’t have access to enough information about them. A new survey aims to help tackle the problem
How much do you know about the treatments available for people with later-stage Parkinson’s disease? A new survey from the European Parkinson’s Disease Association (EPDA) and UK-based company Britannia Pharmaceuticals is investigating what information people with the condition receive about therapies for so-called ‘advanced’ Parkinson’s, and about non-oral therapies.
“‘Advanced’ therapies, as they are often referred to, are a fundamental topic for people with Parkinson’s, their families and carers as the different therapies on offer can often lead to highly effective results,” says Russell Patten, director general of the EPDA.
“And yet it is clear from various forms of research that not enough information or awareness is provided to the Parkinson’s community from healthcare professionals. We want to try and change this reality.”
Take part in the survey
In later-stages of the condition, oral medications can be less effective in treating symptoms – and research suggests that starting non-oral therapies at an earlier stage may lead to an improved quality of life that lasts for a longer time.
Patten describes the fact that many do not receive the right information at the right time as a “serious problem” for people across the world which “potentially prohibits them from receiving the optimal treatment”. Through the new survey, launched on Wednesday 31 March, the EPDA and Britannia hope to identify gaps in knowledge and improve awareness of treatment options – with the ultimate goal of supporting “more timely adoption of ‘advanced’ therapies”.
Participants are invited to complete around 20 multiple-choice questions in an online questionnaire, focused on their perception and knowledge about treatment options – particularly those for ‘advanced’ Parkinson’s.
People of all ages and at all stages of the condition – along with their carers – are encouraged to take part, regardless of when they were diagnosed.
“We are excited to be working with Britannia Pharmaceuticals on this important survey,” adds Patten. “We hope it will lead to valuable information and awareness that can help empower the Parkinson’s community to discuss alternative therapies that may suit them better with their healthcare professionals.”
To find out more about Parkinson’s therapies, please visit the EPDA website.
Share this story
£1.2m award for Parkinson’s disease drug project
A team of researchers are developing an innovative treatmentREAD MORE
Why we need to talk about death and Parkinson’s
Webinar panellists share their thoughts on a difficult topicREAD MORE
“Quick, simple and painless”: a new way to diagnose Parkinson’s disease?
An “innovative” test that could help improve diagnosisREAD MORE